ALEMBIC PHARMA has announced its results for the quarter ended September 2019. Here is a detailed performance review of the same:
No. of Mths Qtr. Ending | 3 Sep-18* | 3 Jun-19* | 3 Sep-19* | QoQ Change | YoY Change | |
---|---|---|---|---|---|---|
Net Sales | Rs m | 11,271 | 9,489 | 12,409 | 30.8% | 10.1% |
Other income | Rs m | 24 | 33 | 4 | -89.0% | -84.8% |
Turnover | Rs m | 11,294 | 9,522 | 12,412 | 30.4% | 9.9% |
Expenses | Rs m | 8,247 | 7,240 | 8,954 | 23.7% | 8.6% |
Gross profit | Rs m | 3,023 | 1,964 | 3,455 | 76.0% | 14.3% |
Depreciation | Rs m | 286 | 354 | 360 | 1.6% | 25.6% |
Interest | Rs m | 58 | 50 | 71 | 42.0% | 21.8% |
Profit before tax | Rs m | 2,703 | 1,593 | 3,029 | 90.1% | 12.1% |
Tax | Rs m | 703 | 360 | 525 | 45.9% | -25.3% |
Profit after tax | Rs m | 2,000 | 1,233 | 2,504 | 103.0% | 25.2% |
Gross profit margin | % | 26.8 | 20.7 | 27.8 | ||
Effective tax rate | % | 26.0 | 22.6 | 17.3 | ||
Net profit margin | % | 17.7 | 13.0 | 20.2 |
To see how ALEMBIC PHARMA has performed over the last eight quarters,please visit here.
Free Guide: Find the Next Crorepati Stock in this Futuristic Industry
Over the last one year,ALEMBIC PHARMA share price has moved down from Rs 601.6 to Rs 561.0, registering a Loss of Rs 40.6 or around 6.7%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,342.2 (up 0.9%). Over the last one year it has moved down from 14,632.9 to 13,342.2, a gain of 1,291 points (down 8.8%).
Overall, the S&P BSE SENSEX is up 16.6% over the year.
At the current price of Rs 561.0, the price to earnings (P/E) ratio of ALEMBIC PHARMA stands at 15.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.9 times.
| |
For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.
For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsWhat to do after every trade.
What we can learn from one of the greatest traders to have ever lived.
This corner of the market could provide more returns than blue chips in 2020.
Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.
2019 will be remembered as the year of great money-making IPOs...
More
| |
Equitymaster requests your view! Post a comment on "ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!